JP2020532589A5 - - Google Patents

Download PDF

Info

Publication number
JP2020532589A5
JP2020532589A5 JP2020534804A JP2020534804A JP2020532589A5 JP 2020532589 A5 JP2020532589 A5 JP 2020532589A5 JP 2020534804 A JP2020534804 A JP 2020534804A JP 2020534804 A JP2020534804 A JP 2020534804A JP 2020532589 A5 JP2020532589 A5 JP 2020532589A5
Authority
JP
Japan
Prior art keywords
pyrazine
amino
naphthalene
imidazole
methylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020534804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532589A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/049081 external-priority patent/WO2019046711A2/en
Publication of JP2020532589A publication Critical patent/JP2020532589A/ja
Publication of JP2020532589A5 publication Critical patent/JP2020532589A5/ja
Pending legal-status Critical Current

Links

JP2020534804A 2017-09-01 2018-08-31 Ire1阻害のための化合物および組成物 Pending JP2020532589A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553320P 2017-09-01 2017-09-01
US62/553,320 2017-09-01
PCT/US2018/049081 WO2019046711A2 (en) 2017-09-01 2018-08-31 COMPOUNDS AND COMPOSITIONS FOR INHIBITING IRE1

Publications (2)

Publication Number Publication Date
JP2020532589A JP2020532589A (ja) 2020-11-12
JP2020532589A5 true JP2020532589A5 (enExample) 2021-10-21

Family

ID=65526075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020534804A Pending JP2020532589A (ja) 2017-09-01 2018-08-31 Ire1阻害のための化合物および組成物

Country Status (13)

Country Link
US (1) US11649237B2 (enExample)
EP (1) EP3675858B1 (enExample)
JP (1) JP2020532589A (enExample)
KR (1) KR20200066301A (enExample)
CN (1) CN111526877B (enExample)
AU (1) AU2018326721B2 (enExample)
BR (1) BR112020004226A2 (enExample)
CA (1) CA3074139A1 (enExample)
IL (1) IL272845B2 (enExample)
MX (1) MX2020002322A (enExample)
SG (1) SG11202001609RA (enExample)
WO (1) WO2019046711A2 (enExample)
ZA (1) ZA202001320B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020059841A1 (ja) * 2018-09-21 2020-03-26 国立大学法人 長崎大学 プリオン病治療薬
CA3131386A1 (en) * 2019-02-27 2020-09-03 Richard Keenan Imidazolopyrazine compounds for ire1 inhibition
BR112021016974A2 (pt) * 2019-02-27 2021-11-30 Optikira Llc Compostos de pirazolopiridina para inibição de ire1
US20230331719A1 (en) * 2020-08-07 2023-10-19 Optikira, LLC Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same
EP4243815A4 (en) * 2020-11-13 2024-10-02 The Regents of the University of California IRE1ALPHA INHIBITORS AND USES THEREOF
JP2025504791A (ja) * 2022-01-07 2025-02-19 アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル ヒドロキシフェニル部分を含む化合物及びその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
EP2283020B8 (en) 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
WO2011047384A2 (en) * 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
CN103079558B (zh) 2010-04-05 2025-09-12 上海复星医药产业发展有限公司 IRE-1α抑制剂
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
MX2015003874A (es) * 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2017152117A1 (en) 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
WO2018102751A1 (en) 2016-12-02 2018-06-07 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors

Similar Documents

Publication Publication Date Title
IL272845B2 (en) Compounds and preparations for inhibiting IRE1
RU2489426C2 (ru) Производные аминопиразола
RU2455288C2 (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
JP2007519754A5 (enExample)
JP2021535134A5 (enExample)
JP2013530240A5 (enExample)
JP2014511869A5 (enExample)
JP2020506946A5 (enExample)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
JP2007523905A5 (enExample)
JP2013507350A5 (enExample)
JP2010540462A5 (enExample)
JP2020515575A5 (enExample)
JP2021501179A5 (enExample)
JP2017537948A5 (enExample)
JP2013507449A5 (enExample)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
RU2006145205A (ru) Терапевтические соединения: пиридин в качестве каркаса
JP2014508128A5 (enExample)
RU2013133800A (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
JP2007531757A5 (enExample)
RU2011134631A (ru) Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
JP2008502700A5 (enExample)
JP2018522823A5 (enExample)
JP2017530199A5 (enExample)